Xeris Biopharma (XERS) News Today $3.49 +0.08 (+2.35%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Xeris Biopharma (NASDAQ:XERS) Shares Up 5.2% - What's Next?Xeris Biopharma (NASDAQ:XERS) Trading 5.2% Higher - Here's WhyDecember 19 at 4:14 PM | marketbeat.comWalleye Capital LLC Invests $3.20 Million in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Walleye Capital LLC purchased a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,121,738 shares of the comDecember 3, 2024 | marketbeat.comXeris to Participate in Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | businesswire.comGSA Capital Partners LLP Sells 578,313 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)GSA Capital Partners LLP cut its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 95.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,350 shares of the company's stocNovember 26, 2024 | marketbeat.comAnalysts Expect Breakeven For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Before LongNovember 18, 2024 | finance.yahoo.comXeris Biopharma downgraded to Neutral from Overweight at Piper SandlerNovember 13, 2024 | markets.businessinsider.comXeris Biopharma price target raised to $6.60 from $6 at H.C. WainwrightNovember 13, 2024 | markets.businessinsider.comPiper Sandler Downgrades Xeris Biopharma Holdings (XERS)November 13, 2024 | msn.comFY2024 EPS Estimates for Xeris Biopharma Raised by AnalystXeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Equities research analysts at HC Wainwright lifted their FY2024 earnings estimates for shares of Xeris Biopharma in a research report issued to clients and investors on Monday, November 11th. HC Wainwright analyst O. Livnat now forecastNovember 13, 2024 | marketbeat.comHC Wainwright Forecasts Weaker Earnings for Xeris BiopharmaXeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Investment analysts at HC Wainwright reduced their FY2027 earnings estimates for shares of Xeris Biopharma in a research report issued to clients and investors on Monday, November 11th. HC Wainwright analyst O. Livnat now expects that tNovember 12, 2024 | marketbeat.comHC Wainwright Forecasts Strong Price Appreciation for Xeris Biopharma (NASDAQ:XERS) StockHC Wainwright upped their price target on Xeris Biopharma from $6.00 to $6.60 and gave the company a "buy" rating in a research report on Monday.November 11, 2024 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Lowered to Neutral Rating by Piper SandlerPiper Sandler lowered shares of Xeris Biopharma from an "overweight" rating to a "neutral" rating and set a $3.00 price target for the company. in a research note on Monday.November 11, 2024 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2024 Earnings Call TranscriptNovember 10, 2024 | msn.comXeris Biopharma Reports Record Third Quarter RevenueNovember 9, 2024 | markets.businessinsider.comXeris Biopharma Holdings Inc (XERS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...November 9, 2024 | finance.yahoo.comXeris Biopharma Holdings, Inc. (XERS) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | seekingalpha.comXeris Biopharma Holdings (NASDAQ:XERS) Stock, Short Interest ReportNovember 8, 2024 | benzinga.comXeris Pharmaceuticals (XERS) Gets a Buy from Craig-HallumNovember 5, 2024 | markets.businessinsider.comXeris Biopharma (XERS) to Release Quarterly Earnings on FridayXeris Biopharma (NASDAQ:XERS) will be releasing earnings before the market opens on Friday, November 8, Zacks reports.November 1, 2024 | marketbeat.comXeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024October 31, 2024 | businesswire.comXeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It AttractiveOctober 25, 2024 | seekingalpha.comOppenheimer Remains a Buy on Xeris Pharmaceuticals (XERS)October 23, 2024 | markets.businessinsider.comSeveral Insiders Invested In Xeris Biopharma Holdings Flagging Positive NewsOctober 9, 2024 | finance.yahoo.comXeris Biopharma: Time For A ReassessmentOctober 9, 2024 | seekingalpha.comXeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)October 4, 2024 | businesswire.comXTX Topco Ltd Sells 223,267 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)XTX Topco Ltd lessened its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 87.5% in the second quarter, according to its most recent filing with the SEC. The firm owned 31,782 shares of the company's stock after selling 223,267 shares during the period. XTX TopcoOctober 2, 2024 | marketbeat.comRenaissance Technologies LLC Acquires 342,300 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Renaissance Technologies LLC increased its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 33.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,351,640 shOctober 1, 2024 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) most popular amongst individual investors who own 53% of the shares, institutions hold 43%September 12, 2024 | finance.yahoo.com3 Penny Stocks to Buy With $500August 30, 2024 | 247wallst.comXERS Jan 2025 5.000 callAugust 24, 2024 | ca.finance.yahoo.comXeris to Participate in Upcoming Investor ConferencesAugust 23, 2024 | finance.yahoo.comXERS Sep 2024 5.000 put (XERS240920P00005000)August 18, 2024 | finance.yahoo.comBrokers Offer Predictions for Xeris Biopharma Holdings, Inc.'s Q3 2024 Earnings (NASDAQ:XERS)Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Stock analysts at HC Wainwright reduced their Q3 2024 earnings estimates for shares of Xeris Biopharma in a research note issued on Wednesday, August 14th. HC Wainwright analyst O. Livnat now expects that the company will earn ($0.10) pAugust 16, 2024 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) to Post FY2027 Earnings of $0.27 Per Share, HC Wainwright ForecastsXeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Equities research analysts at HC Wainwright lowered their FY2027 EPS estimates for Xeris Biopharma in a report issued on Wednesday, August 14th. HC Wainwright analyst O. Livnat now forecasts that the company will post earnings of $0.27August 15, 2024 | marketbeat.comMore Than $20M Bet On Precigen? Check Out These 3 Stocks Under $5 Insiders Are Aggressively BuyingAugust 14, 2024 | benzinga.comXeris Biopharma And 2 Other Penny Stocks Insiders Are BuyingAugust 14, 2024 | msn.comInsider Buying: Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Acquires 4,285 Shares of StockAugust 13, 2024 | insidertrades.comVanguard Group Inc. Grows Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Vanguard Group Inc. grew its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 7.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,606,242 shares of the company's stock after acquiring an additiAugust 13, 2024 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Buys $10,155.45 in StockXeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) Director John P. Schmid acquired 4,285 shares of Xeris Biopharma stock in a transaction on Friday, August 9th. The stock was acquired at an average price of $2.37 per share, with a total value of $10,155.45. Following the purchase, the director now directly owns 20,685 shares in the company, valued at $49,023.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.August 12, 2024 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSXeris Biopharma (NASDAQ:XERS - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.01. Xeris Biopharma had a negative return on equity of 16,662.63% and a negative net margin of 37.58%. The company had revenue of $48.07 million during the quarter, compared to the consensus estimate of $46.80 million. During the same period last year, the business earned ($0.14) EPS.August 10, 2024 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | msn.comXERS Stock Earnings: Xeris Biopharma Holdings Beats EPS, Beats Revenue for Q2 2024August 8, 2024 | investorplace.comXeris Biopharma Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | finance.yahoo.comCraig-Hallum Keeps Their Buy Rating on Xeris Pharmaceuticals (XERS)August 7, 2024 | markets.businessinsider.comXERS Aug 2024 2.000 put (XERS240816P00002000)July 24, 2024 | finance.yahoo.comLeerink Partnrs Comments on Xeris Biopharma Holdings, Inc.'s Q2 2024 Earnings (NASDAQ:XERS)Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Leerink Partnrs boosted their Q2 2024 earnings per share estimates for Xeris Biopharma in a note issued to investors on Tuesday, July 9th. Leerink Partnrs analyst R. Ruiz now expects that the company will earn ($0.11) per share for theJuly 11, 2024 | marketbeat.comXeris Biopharma unveils CEO succession plan, John Shannon to lead companyJuly 8, 2024 | proactiveinvestors.comXeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)July 3, 2024 | businesswire.comInvenomic Capital Management LP Takes Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Invenomic Capital Management LP bought a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 568,619 shares of the company's stock, valued at approxiJune 11, 2024 | marketbeat.comXeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing's Syndrome Patients at ENDO 2024June 3, 2024 | businesswire.com Get Xeris Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin XERS Media Mentions By Week XERS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XERS News Sentiment▼0.670.60▲Average Medical News Sentiment XERS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XERS Articles This Week▼12▲XERS Articles Average Week Get Xeris Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AKRO News TARS News AMPH News IRON News CGON News HRMY News GLPG News XNCR News EVO News ARQT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XERS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XERS Stock Alerts